DEPLOYDatabase

Robot model

ReoAmbulator

exoskeletoncommercialby Motorika

ReoAmbulator is Motorika's fixed robotic gait-rehabilitation system for patients recovering from stroke or other neuromuscular conditions, listed in FDA GUDID…

Track ReoAmbulator
Manufacturer
Motorika
Form factor
exoskeleton
Maturity
commercial
Lifecycle
active
Deployments
2

Deploy Watch

Track ReoAmbulator on Deploy.

We notify you when a verified state change lands on the record, not when the company issues a claim.

Track ReoAmbulator

Key facts

FDA GUDID listing

AccessGUDID DI 07290017844305: ReoAmbulator model B, catalog RA01-0000-00, Motorika Medical (Israel), in commercial distribution (version date 10 Jun 2019).

Intended use (FDA GUDID)

Robotic powered exercise equipment to redevelop muscles and restore joint motion after stroke or another neuromuscular condition.

Design (FDA GUDID)

One modular robotic guide for passive and active lower-limb motion, with sensors for motion control and patient performance. Prescription use, not single-use.

Data & sources

Research

1

Web sources

1

2 sources backing this record.View all →

Pricing

No verified price is on record for ReoAmbulator. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

Deployments (2)

ReoAmbulator on the deployment map

View the global map

Where ReoAmbulator is verified operating. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Safety record

No incidents on record for ReoAmbulator.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (2)

  1. https://exoskeletonreport.com/2015/02/businesses-that-have-or-are-exploring-exoskeleton-products-in-alphabetical-order/
  2. https://accessgudid.nlm.nih.gov/devices/07290017844305

Mentioned on (1)

Registry pages whose text names ReoAmbulator.

Common questions

What is ReoAmbulator?
ReoAmbulator is Motorika's fixed robotic gait-rehabilitation system for patients recovering from stroke or other neuromuscular conditions, listed in FDA GUDID as in commercial distribution.
How much does ReoAmbulator cost?
ReoAmbulator's price is not publicly disclosed. DEPLOY has no verified price on record for ReoAmbulator from Motorika. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is ReoAmbulator actually deployed in the real world?
Yes. ReoAmbulator is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Who makes ReoAmbulator?
ReoAmbulator is made by Motorika, based in Caesarea, Israel, founded in 2004.
Where is ReoAmbulator deployed?
2 verified deployments of ReoAmbulator are on the DEPLOY registry, including at Israel, Asia, United States.
Can you buy ReoAmbulator?
ReoAmbulator is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
What are alternatives to ReoAmbulator?
On the DEPLOY registry, comparable exoskeleton robots to ReoAmbulator include Ant-H1 Pro, Cyberdyne HAL, German Bionic Cray X, HANK.
How does ReoAmbulator compare to Ant-H1 Pro?
ReoAmbulator and Ant-H1 Pro (Kenqing Technology · 5 deployments) are both exoskeleton robots on the DEPLOY registry. ReoAmbulator has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is ReoAmbulator a top exoskeleton?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, ReoAmbulator ranks in roughly the top 44% of exoskeleton models tracked by the registry.
What is ReoAmbulator's maturity stage?
ReoAmbulator is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
Is ReoAmbulator safe?
ReoAmbulator has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-10-12

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-10-12

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: exoskeleton

Sources by quality tier

1
unclassified
Unclassified source
1
primary-academic-peer-reviewed
Peer-reviewed clinical / academic

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for ReoAmbulator.

Recent coverage

ReoAmbulator in third-party press

Motorika

Jul 29, 2022

Motorika to Introduce Optimal-G™ Pro State-of-the-art Gait Rehabilitation System at 2019 APTA Combined Sessions Meeting in Washington DC

Jan 22, 2019